Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Dropbox Inc (DBX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Dropbox Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.76 (market cap $8.04B), while Dropbox Inc trades at $30.7 (market cap $6.99B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Dropbox Inc is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | DBX | |
|---|---|---|
Market Cap | $8.04B | $6.99B |
Sector | Health | Technology |
52-Week High | $339.75 | $32.17 |
52-Week Low | $241.71 | $22.06 |
Enterprise Value | $7.85B | $9.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Dropbox (DBX) trades at $29.58, up 1.34% on the day, near the analyst consensus price target of $30. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate potential overbought conditions. Fundamentally, the company maintains robust profitability with a net income margin of 18.71% and has beaten earnings estimates for three consecutive quarters. Recent news highlights a new $900 million stock repurchase program and a CEO transition plan announced in May 2026.
The outlook is balanced with solid fundamentals and shareholder returns offset by high debt levels and mixed analyst sentiment. Investment appeal lies in consistent earnings beats and capital return initiatives, but risks include elevated leverage and competitive pressures in cloud storage. The stock presents a moderate opportunity with cautious optimism warranted given its valuation near target prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
